Article
Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations.
Nature reviews. Urology - 1 Apr 2023
Rajwa Pawel, Quhal Fahad, Pradere Benjamin, Gandaglia Giorgio, Ploussard Guillaume, Leapman Michael S, Gore John L, Paradysz Andrzej, Tilki Derya, Merseburger Axel S, Morgan Todd M, Briganti Alberto, Palapattu Ganesh S, Shariat Shahrokh F
Abstract excerpt
Mutations in the BRCA1 and BRCA2 tumour suppressor genes are associated with prostate cancer risk; however, optimal screening protocols for individuals with these mutations have been a subject of debate. Several prospective studies of prostate cancer incidence and screening among BRCA1/2 mutation carriers have indicated at least a twofold to fourfold increase in prostate cancer risk among carriers of BRCA2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.